aging-biology
(3)
Life Biosciences Put Its Aging Theory in One Eye
The Boston biotech began with the immense ambition of treating aging itself. Its first human test is far narrower: can a gene therapy safely coax damaged optic-nerve cells toward a younger state?
The Cell That Forgot How to Be Young
NewLimit wants to make an old cell useful again without making it forget what kind of cell it is. Its first test of that idea is headed from the liver lab toward human trials.
Rejuvenation Technologies Inc.
Rejuvenation Technologies is a Stanford-spun biotech developing modified-mRNA therapeutics that temporarily switch on telomerase to lengthen telomeres and reverse cellular aging in specific tissues. Its lead programs target fibrotic and age-related diseases such as pulmonary fibrosis, chronic liver disease and bone-marrow failure, delivered by proprietary tissue-targeted lipid nanoparticles. Backed by Khosla Ventures and Y Combinator, the company holds 50+ patents and is advancing toward Phase I clinical readouts.